<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34775534</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1435-4373</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>European journal of clinical microbiology &amp; infectious diseases : official publication of the European Society of Clinical Microbiology</Title><ISOAbbreviation>Eur J Clin Microbiol Infect Dis</ISOAbbreviation></Journal><ArticleTitle>What have we learned from the first to the second wave of COVID-19 pandemic? An international survey from the ESCMID Study Group for Infection in the Elderly (ESGIE) group.</ArticleTitle><Pagination><StartPage>281</StartPage><EndPage>288</EndPage><MedlinePgn>281-288</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10096-021-04377-1</ELocationID><Abstract><AbstractText>The purpose of this survey is to explore changes in the management of COVID-19 during the first versus the second wave, with particular emphasis on therapies, antibiotic prescriptions, and elderly care. An internet-based questionnaire survey was distributed to European Society of Clinical Microbiology and Infectious Diseases (ESCMID) members. Therapeutic approach to patients with mild-to-moderate (PiO<sub>2</sub>/FiO<sub>2</sub> 200-350) and severe (PiO<sub>2</sub>/FiO<sub>2</sub>&#x2009;&lt;&#x2009;200) COVID-19, antibiotic use, and reasons for excluding patients from the intensive care unit (ICU) were investigated. A total of 463 from 21 countries participated in the study. Most representatives were infectious disease specialists (68.3%). During the second wave of pandemic, physicians abandoned the use of hydroxychloroquine, lopinavir/ritonavir, and azithromycin in favor of dexamethasone, low-molecular weight heparin (LMWH), and remdesivir in mild-to-moderate COVID-19. In critically ill patients, we detected an increased use of high-dose steroids (51%) and a decrease in tocilizumab use. The use of antibiotics at hospital admission decreased but remained high in the second wave. Age was reported to be a main consideration for exclusion of patients from ICU care by 25% of responders; a third reported that elderly were not candidates for ICU admission in their center. The decision to exclude patients from ICU care was based on the individual decision of an intensivist in 59.6% of cases. The approach of physicians to COVID-19 changed over time following evidence accumulation and guidelines. Antibiotic use at hospital admission and decision to exclude patients from ICU care remain critical aspects that should be better investigated and harmonized among clinicians.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tiseo</LastName><ForeName>Giusy</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Azienda Ospedaliera Universitaria Pisana, Department of Clinical and Experimental Medicine, University of Pisa, Via Paradisa 2, 56124, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yahav</LastName><ForeName>Dafna</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Rabin Medical Center, Beilinson Campus, Petah-Tikva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Mical</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tinelli</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Istituto Auxologico Italiano, IRCCS, San Luca Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gavazzi</LastName><ForeName>Gaetan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>University Clinics of Geriatrics, University Hospital of Grenoble-Alpes, University of Grenoble Alpes, Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mussini</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prendki</LastName><ForeName>Virginie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Internal Medicine of the Aged, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falcone</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Azienda Ospedaliera Universitaria Pisana, Department of Clinical and Experimental Medicine, University of Pisa, Via Paradisa 2, 56124, Pisa, Italy. marco.falcone@unipi.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Clin Microbiol Infect Dis</MedlineTA><NlmUniqueID>8804297</NlmUniqueID><ISSNLinking>0934-9723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558899">lopinavir-ritonavir drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibiotics</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Elderly</Keyword><Keyword MajorTopicYN="N">Intensive care unit</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>14</Day><Hour>21</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34775534</ArticleId><ArticleId IdType="pmc">PMC8590524</ArticleId><ArticleId IdType="doi">10.1007/s10096-021-04377-1</ArticleId><ArticleId IdType="pii">10.1007/s10096-021-04377-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Contou D, Fraiss&#xe9; M, Pajot O, Tirolien JA, Mentec H, Plantef&#xe8;ve G. Comparison between first and second wave among critically ill COVID-19 patients admitted to a French ICU: no prognostic improvement during the second wave? Crit Care. 2021;25:3. doi: 10.1186/s13054-020-03449-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03449-6</ArticleId><ArticleId IdType="pmc">PMC7780592</ArticleId><ArticleId IdType="pubmed">33397421</ArticleId></ArticleIdList></Reference><Reference><Citation>Azoulay E, de Waele J, Ferrer R, Staudinger T, Borkowska M, Povoa P, et al. International variation in the management of severe COVID-19 patients. Crit Care. 2020;24:486. doi: 10.1186/s13054-020-03194-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03194-w</ArticleId><ArticleId IdType="pmc">PMC7403819</ArticleId><ArticleId IdType="pubmed">32758266</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehra MR, Ruschitzka F, Patel AN. Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020;395:1820. doi: 10.1016/S0140-6736(20)31324-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31324-6</ArticleId><ArticleId IdType="pmc">PMC7274621</ArticleId><ArticleId IdType="pubmed">32511943</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693&#x2013;704. doi: 10.1056/NEJMoa2021436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Sterne JAC, Murthy S, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. JAMA. 2020;324:1330&#x2013;41. doi: 10.1001/jama.2020.17023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.17023</ArticleId><ArticleId IdType="pmc">PMC7489434</ArticleId><ArticleId IdType="pubmed">32876694</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181:24&#x2013;31. doi: 10.1001/jamainternmed.2020.6615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.6615</ArticleId><ArticleId IdType="pmc">PMC7577199</ArticleId><ArticleId IdType="pubmed">33080005</ArticleId></ArticleIdList></Reference><Reference><Citation>REMAP-CAP Investigators. Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384:1491&#x2013;1502. doi: 10.1056/NEJMoa2100433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2100433</ArticleId><ArticleId IdType="pmc">PMC7953461</ArticleId><ArticleId IdType="pubmed">33631065</ArticleId></ArticleIdList></Reference><Reference><Citation>Stebbing J, S&#xe1;nchez Nievas G, Falcone M, Youhanna S, Richardson P, Ottaviani S, et al. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Sci Adv. 2020;7:eabe4724. doi: 10.1126/sciadv.abe4724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abe4724</ArticleId><ArticleId IdType="pmc">PMC7775747</ArticleId><ArticleId IdType="pubmed">33187978</ArticleId></ArticleIdList></Reference><Reference><Citation>Libster R, P&#xe9;rez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384:610&#x2013;618. doi: 10.1056/NEJMoa2033700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2033700</ArticleId><ArticleId IdType="pmc">PMC7793608</ArticleId><ArticleId IdType="pubmed">33406353</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, V&#xe1;zquez C, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021;384:619&#x2013;629. doi: 10.1056/NEJMoa2031304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2031304</ArticleId><ArticleId IdType="pmc">PMC7722692</ArticleId><ArticleId IdType="pubmed">33232588</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) BMJ. 2020;371:m3939. doi: 10.1136/bmj.m3939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3939</ArticleId><ArticleId IdType="pmc">PMC7578662</ArticleId><ArticleId IdType="pubmed">33093056</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulcini C, Leibovici L. CMI Editorial Office. CMI guidance for authors of surveys. Clin Microbiol Infect. 2016;22:901&#x2013;02. doi: 10.1016/j.cmi.2016.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2016.08.015</ArticleId><ArticleId IdType="pubmed">27599691</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragkou PC, Belhadi D, Peiffer-Smadja N, Moschopoulos CD, Lescure FX, Janocha H, et al. ESCMID Study Group for Respiratory Viruses. Review of trials currently testing treatment and prevention of COVID-19. Clin Microbiol Infect. 2020;26:988&#x2013;98. doi: 10.1016/j.cmi.2020.05.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.05.019</ArticleId><ArticleId IdType="pmc">PMC7245266</ArticleId><ArticleId IdType="pubmed">32454187</ArticleId></ArticleIdList></Reference><Reference><Citation>Definition Task Force ARDS, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307:2526&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference><Reference><Citation>Smythe MA, Priziola J, Dobesh PP, et al. Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016;41:165&#x2013;186. doi: 10.1007/s11239-015-1315-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-015-1315-2</ArticleId><ArticleId IdType="pmc">PMC4715846</ArticleId><ArticleId IdType="pubmed">26780745</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcone M, Tiseo G, Giordano C, Wirth D, Cuker A, Wittkowsky AK. Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study. J Antimicrob Chemother. 2021;76:1078&#x2013;1084. doi: 10.1093/jac/dkaa530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkaa530</ArticleId><ArticleId IdType="pmc">PMC7799007</ArticleId><ArticleId IdType="pubmed">33374002</ArticleId></ArticleIdList></Reference><Reference><Citation>Fihn SD, Perencevich E, Bradley SM. Caution needed on the use of chloroquine and hydroxychloroquine for Coronavirus Disease 2019. JAMA Netw Open. 2020;3:e209035. doi: 10.1001/jamanetworkopen.2020.9035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.9035</ArticleId><ArticleId IdType="pubmed">32330276</ArticleId></ArticleIdList></Reference><Reference><Citation>Mussini C, Falcone M, Nozza S, Sagnelli C, Parrella R, Meschiari M, et al. Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT) Clin Microbiol Infect. 2021;27:389&#x2013;395. doi: 10.1016/j.cmi.2020.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.12.011</ArticleId><ArticleId IdType="pmc">PMC7833273</ArticleId><ArticleId IdType="pubmed">33359375</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamaati H, Hashemian SM, Farzanegan B, Malekmohammad M, Tabarsi P, Marjani M, et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial. Eur J Pharmacol. 2021;897:173947. doi: 10.1016/j.ejphar.2021.173947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2021.173947</ArticleId><ArticleId IdType="pmc">PMC7885705</ArticleId><ArticleId IdType="pubmed">33607104</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadikia K, Hashemi SJ, Khodavaisy S, Getso MI, Alijani N, Badali H et al (2021) The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis. Mycoses 64:798&#x2013;808</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8013756</ArticleId><ArticleId IdType="pubmed">33590551</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcone M, Tiseo G, Barbieri G, Galfo V, Russo A, Virdis A, et al. Role of low-molecular-weight heparin in hospitalized patients with severe acute respiratory syndrome coronavirus 2 pneumonia: a prospective observational study. Open Forum Infect Dis. 2020;7:ofaa563. doi: 10.1093/ofid/ofaa563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofaa563</ArticleId><ArticleId IdType="pmc">PMC7717381</ArticleId><ArticleId IdType="pubmed">33365358</ArticleId></ArticleIdList></Reference><Reference><Citation>The REMAP-CAP, ACTIV-4a, ATTACC Investigators, Zarychanski R (2021) Therapeutic anticoagulation in critically ill patients with Covid-19 &#x2013; Preliminary Report. MedRxiv Posted March 12, 2021</Citation></Reference><Reference><Citation>REMAP-CAP Investigators. Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021;384:1491&#x2013;1502. doi: 10.1056/NEJMoa2100433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2100433</ArticleId><ArticleId IdType="pmc">PMC7953461</ArticleId><ArticleId IdType="pubmed">33631065</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637&#x2013;1645. doi: 10.1016/S0140-6736(21)00676-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00676-0</ArticleId><ArticleId IdType="pmc">PMC8084355</ArticleId><ArticleId IdType="pubmed">33933206</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute of Health (NIH). Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Available at: https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/interleukin-6-inhibitors/. Accessed 28 Oct 2021</Citation><ArticleIdList><ArticleId IdType="pubmed">34003615</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Vidal C, Sanjuan G, Moreno-Garc&#xed;a E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al. COVID-19 Researchers Group. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021;27:83&#x2013;8. doi: 10.1016/j.cmi.2020.07.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.07.041</ArticleId><ArticleId IdType="pmc">PMC7836762</ArticleId><ArticleId IdType="pubmed">32745596</ArticleId></ArticleIdList></Reference><Reference><Citation>Langford BJ, So M, Raybardhan S, Leung V, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26:1622&#x2013;1629. doi: 10.1016/j.cmi.2020.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.07.016</ArticleId><ArticleId IdType="pmc">PMC7832079</ArticleId><ArticleId IdType="pubmed">32711058</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcone M, Tiseo G, Nicastro M, Leonildi A, Vecchione A, Casella C, et al. Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-Negative infections in ICU patients. Clin Infect Dis. 2021;72:2021&#x2013;2024. doi: 10.1093/cid/ciaa1410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1410</ArticleId><ArticleId IdType="pubmed">32941593</ArticleId></ArticleIdList></Reference><Reference><Citation>Huttner BD, Catho G, Pano-Pardo JR, Pulcini C, Schouten J. COVID-19: don't neglect antimicrobial stewardship principles! Clin Microbiol Infect. 2020;26:808&#x2013;810. doi: 10.1016/j.cmi.2020.04.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.04.024</ArticleId><ArticleId IdType="pmc">PMC7190532</ArticleId><ArticleId IdType="pubmed">32360446</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis EG, Breckons M, Lee RP, Dotchin C, Walker R. Rationing care by frailty during the COVID-19 pandemic. Age Ageing. 2021;50:7&#x2013;10. doi: 10.1093/ageing/afaa171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afaa171</ArticleId><ArticleId IdType="pmc">PMC7454249</ArticleId><ArticleId IdType="pubmed">32725156</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprung CL, Joynt GM, Christian MD, Truog RD, Rello J, Nates JL. Adult ICU triage during the coronavirus disease 2019 pandemic: who will live and who will die? recommendations to improve survival. Crit Care Med. 2020;48:1196&#x2013;1202. doi: 10.1097/CCM.0000000000004410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000004410</ArticleId><ArticleId IdType="pmc">PMC7217126</ArticleId><ArticleId IdType="pubmed">32697491</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung C, Flaatten H, Fj&#xf8;lner J, Bruno RR, Wernly B, Artigas A, et al. The impact of frailty on survival in elderly intensive care patients with COVID-19: the COVIP study. Crit Care. 2021;25:149. doi: 10.1186/s13054-021-03551-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-021-03551-3</ArticleId><ArticleId IdType="pmc">PMC8054503</ArticleId><ArticleId IdType="pubmed">33874987</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong E, Chan M, Tan HN, Lim WS. COVID-19: use of the clinical frailty scale for critical care decisions. J Am Geriatr Soc. 2020;68:E30&#x2013;E32. doi: 10.1111/jgs.16528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.16528</ArticleId><ArticleId IdType="pmc">PMC7267651</ArticleId><ArticleId IdType="pubmed">32359076</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence. COVID-19 Rapid Guideline: Critical Care. 2020. www.nice.org.uk/guidance/ng159. Accessed April 6, 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">33497153</ArticleId></ArticleIdList></Reference><Reference><Citation>Prendki V, Tau N, Avni T, Falcone M, Falcone M, Huttner A, Kaiser L, et al. ESCMID Study Group for Infections in the Elderly (ESGIE). A systematic review assessing the under-representation of elderly adults in COVID-19 trials. BMC Geriatr. 2020;20:538. doi: 10.1186/s12877-020-01954-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12877-020-01954-5</ArticleId><ArticleId IdType="pmc">PMC7749979</ArticleId><ArticleId IdType="pubmed">33342426</ArticleId></ArticleIdList></Reference><Reference><Citation>Razonable RR, Pawlowski C, O'Horo JC, Arndt LL, Arndt R, Bierle DM, et al (2021) Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19. EClinicalMedicine 101102</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8404031</ArticleId><ArticleId IdType="pubmed">34485873</ArticleId></ArticleIdList></Reference><Reference><Citation>Falcone M, Tiseo G, Valoriani B, Barbieri C, Occhineri S, Mazzetti P, et al (2021) Efficacy of bamlanivimab/etesevimab and casirivimab/imdevimab in preventing progression to severe covid-19 and role of variants of concern. Infect Dis Ther. 1&#x2013;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8386337</ArticleId><ArticleId IdType="pubmed">34435337</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>